Meet the editor

Jindong Chen earned his Ph.D. from the Karolinska Institute, Sweden. He is an active member of the American Association for Cancer Research (AACR) and the chief technology officer at Exploring Health, LLC. He is also a professor at Zunyi Medical University, China, and a former research associate professor and kidney laboratory co-director at the University of Rochester Medical Center, USA. When serving as a research scientist at

Van Andel Research Institute, USA, and a senior scientist at the National Cancer Center Singapore and Duke-NUS University Medical School, USA, Dr. Chen position-cloned two cancer-related genes, *NORE1* and *LSAMP*, and participated in the identification of *HRPT2* and *FLCN*. He subsequently developed several *FLCN*  and *HRPT2* knockout mouse models. For those achievements, he was awarded at the 94th and 100th AACR annual meetings. Currently, Dr. Chen is working on the development of anti-metastasis drugs.

## Contents



Preface

Kidney cancer is the sixth most common malignant disease in men and the tenth most common in women. It accounts for 5% of male and 3% of female malignancies. With the development and improvement of new techniques, updated knowledge and

information are essential for the management of renal cell carcinoma (RCC).

been decreasing although its incidence is increasing.

and effort, this book would not have been possible.

In the past decade, the use of improved diagnostic methods such as ultrasound, contrast-enhanced ultrasound (CEUS), computed tomography (CT) scan, magnetic resonance imaging (MRI), and positron emission tomography (PET)/CT scan has significantly increased the detection rate of RCC. Additionally, robotic platforms with the integration of imaging approaches have been adopted in RCC surgery, which has transformed the paradigm in the surgical treatment of RCC and will continue to change it in the future. With the use of robot-assisted partial nephrectomy in RCC surgery, urologists can maximize functional and oncologic outcomes in nephron preservation and complication-free recovery. For advanced or metastatic RCC, the progress in targeted therapy, immunotherapy, and combination therapy has been improving patient survival outcomes. For these reasons, the mortality of RCC has

With international experts sharing their experience, knowledge, and review, this book provides updated information on the epidemiology, genetics, diagnosis, screening, and advances in treatment and management of RCC to treating physicians as well

as their patients. The book is also a useful resource for researchers in the field.

I would like to give my sincere thanks to all the contributing authors as well as the team at IntechOpen, especially Author Service Manager Ms. Martina Scerbe and Publishing Process Manager Ms. Paula Gavran. Without their support, dedication,

**Jindong Chen**

Chief Technology Officer, Exploring Health, LLC Guangzhou, China
